(S002) Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Soft Tissue Sarcoma MetastasesApril 15th 2014
Radiobiology studies suggest that soft tissue sarcoma (STS) is a radioresistant tumor. We reviewed our institutional outcomes of patients treated with stereotactic body radiation therapy for metastatic STS.
(S001) Limb-Sparing Surgery and Intraoperative Radiotherapy in the Treatment of Primary, Nonmetastatic Extremity and Limb-Girdle Soft Tissue SarcomaApril 15th 2014
To investigate the efficacy and morbidity of limb-sparing surgery with intraoperative radiotherapy (IORT) for patients with primary, nonmetastatic extremity and limb-girdle soft tissue sarcoma (STS) at high risk for recurrence.
(S003) Disparities in Stage at Diagnosis and Survival in Adult Cancer Patients According to Insurance StatusApril 15th 2014
Among patients with the top 10 causes of cancer death, those with Medicaid or without insurance were more likely to present with advanced-stage disease. This group also experienced worse survival when controlling for demographic information, stage at diagnosis, and receipt of definitive treatment.
(S004) Radiation Publications Underrepresented in High-Impact General Medical and Oncology JournalsApril 15th 2014
Cancer treatment studies are well represented in high-impact oncology as well as general medical journals. We sought to evaluate the distribution and characteristics of oncology studies by intervention (radiation, surgery, cytotoxic chemotherapy, or targeted/systemic agents) in six high-impact oncology and general medical journals.
(S005) Adjuvant Radiotherapy in Stage II Endometrial Carcinoma: Is Brachytherapy Alone Sufficient for Local Control?April 15th 2014
To evaluate recurrence patterns and overall survival in patients treated with adjuvant radiation after surgical staging for stage II endometrial carcinoma. Secondary goals include identification of prognostic factors for recurrence.
(S006) Extended-Field IMRT With Concomitant Boost for Node-Positive Cervical Cancer: Analysis of Regional Control Rate and Recurrence PatternApril 15th 2014
We have been treating patients with positive pelvic nodes with extended-field intensity-modulated radiation therapy (IMRT) to address the PA region prophylactically with a concomitant boost to the involved nodes. The purpose of this study is to assess regional control rates and recurrence patterns with this technique.
(S007) Stereotactic Radiosurgery to the Brain With Concurrent BRAF Inhibitors for Melanoma MetastasesApril 15th 2014
Linear accelerator-based stereotactic radiosurgery (SRS) is an effective treatment for selected melanoma patients with brain metastases. Recently, BRAF inhibitors have shown efficacy in stage IV melanoma. We sought to determine the effectiveness of SRS in patients with melanoma who are also being treated with BRAF inhibitors.
(S008) Use of Mobile Devices for Creation of Survivorship Care PlansApril 15th 2014
Cancer survivors may experience myriad late effects, and the Institute of Medicine recommends that survivorship care plans be provided to all. This study explores the willingness of health care providers (HCPs) and survivors to utilize mobile devices (MDs) for this purpose.
(S010) Prospective and Real-Time Data Analysis of Image-Guided Radiotherapy Across a Multinational Pediatrics Consortium: Methodology and ConsiderationsApril 15th 2014
We describe a method for prospectively collecting real-time, longitudinal datasets evaluating central nervous system (CNS)-directed IGRT across a multinational pediatrics consortium.
(S015) Temporal Lobe Radionecrosis After Skull Base Radiotherapy: Dose-Volume PredictorsApril 15th 2014
Temporal lobe radionecrosis is a potential complication of high-dose radiation therapy for skull base tumors. The risk of radionecrosis increases with absolute doses greater than 60 Gy, but little data are available regarding potential partial volume effects when higher-dose conventionally fractionated radiotherapy is employed.
(S012) Prognostic Value of Radiographic Extracapsular Extension in Locally Advanced Non-Oropharyngeal Head and Neck Squamous Cell CancersApril 15th 2014
Previous data from our institution suggest that imaging evidence of extracapsular extension, identified on pretreatment CT scans, independently predicts for worse distant control and survival for oropharyngeal squamous cell cancer (OPC) patients undergoing radiation therapy. In this present study, we sought to validate these findings in non-OPC head and neck squamous cell cancers.
(S016) Head and Neck Second Primary Cancer Rates in the HPV Era: A SEER AnalysisApril 15th 2014
Our objective was to analyze the incidence of second primary cancer limited to the head and neck in a population with primary squamous cell carcinoma of the head and neck and its temporal trends in the human papillomavirus (HPV) era.
(S017) Long-Term Outcome of Intensity-Modulated Radiation Therapy in Pediatric CraniopharyngiomaApril 15th 2014
The purpose of this study is to report the long-term progression-free survival (PFS), overall survival (OS), and late-toxicity outcomes in pediatric patients with craniopharyngioma who have been treated with IMRT.
(S018) Early Tumor Perfusion Changes Predict Time to Progression in Patients With Recurrent Low-Grade Gliomas Treated With Everolimus Under a Phase II Clinical TrialApril 15th 2014
Low-grade gliomas (LGGs) are slow-growing, primary brain tumors that frequently recur after primary surgical treatment. Recent work has established the activation of the PI3K/mTOR pathway in most LGGs, raising the possibility that mTOR inhibitors, such as everolimus (RAD001), may benefit patients with LGG. Early imaging markers of treatment response and disease progression are needed to assess patients undergoing investigational therapy.
(S020) Availability of Single-Fraction Palliative Radiotherapy for Cancer Patients Receiving End-of-Life Care Within the Veterans Healthcare AdministrationApril 15th 2014
Single-fraction palliative radiotherapy for bone metastasis appears to be much more available for cancer patients receiving end-of-life care within the United Veterans Healthcare Administration when compared with the general US health care system.
(S021) Central Versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell Lung CancerApril 15th 2014
The goal of this study is to compare survival, local control, and toxicity outcomes for non–small-cell lung cancer patients treated with SBRT for centrally versus peripherally located tumors.
(S022) Influence of Preoperative Radiation Field on Postoperative Leak Rates in Esophageal Cancer Patients After Trimodality TherapyApril 15th 2014
Neoadjuvant chemoradiation is a standard treatment of locally advanced esophageal cancer. Preventive strategies to minimize postoperative morbidity will be important to help improve the clinical outcomes of patients. We investigated the factors associated with an increased incidence of anastomotic leaks among patients treated with neoadjuvant chemoradiation.
(S024) Correlation of Survival to CBCT-Based Tumor Response During Chemoradiation in Patients With Stage III Non–Small-Cell Lung CancerApril 15th 2014
We evaluated the correlation between patient survival and reduction in gross tumor volume (GTV) using weekly cone-beam computed tomography (CBCT) to assess whether this could be prognostic of survival. We hypothesized that a greater percent decline in primary lung tumor volume during the course of treatment would correlate to improved patient survival.
(S025) Radiation-Induced Increases in PARP1 Activity Predict for Long-Term Radiosensitization by PARP1 Inhibition in Preclinical Breast Cancer ModelsApril 15th 2014
The goal of this study was to optimize combination therapy with PARP1 inhibition and radiation for clinical assessment by establishing the most effective drug/radiation treatment schedule, determining the degree of PARP1-mediated radiosensitization across a range of drug doses, and identifying early biomarkers predictive of long-term treatment efficacy in preclinical BCa models.
(S026) Postmastectomy Radiation Therapy for T3N0 Breast Cancer: A SEER AnalysisApril 15th 2014
There is conflicting evidence regarding the benefit of postmastectomy radiation therapy (PMRT) for pathologic stage T3N0M0 breast cancers. We performed a Surveillance, Epidemiology, and End Results (SEER) analysis to investigate the benefit of PMRT in these patients.
(S027) Patterns of Failure for Rhabdomyosarcoma of the Perineal and Perianal RegionApril 15th 2014
Purpose: Rhabdomyosarcoma of the perineal and perianal region (PRMS) has poor outcomes. We analyzed prognostic factors and patterns of failure, with an emphasis on radiotherapy for locoregional control.
(S028) Sequential Short-Course Radiotherapy and FOLFOX Chemotherapy as Preoperative Therapy for Rectal Cancer Provides Increased DFS Compared With Historical ControlsApril 15th 2014
To compare rates of pathologic response, downstaging, local control, and treatment-related toxicity in patients treated in a prospective phase II trial of preoperative short-course radiotherapy and sequential FOLFOX (folinic acid, fluorouracil, oxaliplatin) chemotherapy with patients treated at our institution with preoperative long-course chemoradiotherapy and adjuvant chemotherapy.
(S029) Patient-Reported Voice and Speech Outcomes and Their Clinical and Dosimetric Predictors After Chemo-IMRT of Oropharyngeal Cancer: A Prospective Longitudinal StudyApril 15th 2014
Although adverse sequelae of chemoradiation (CRT) for head and neck cancer (HNC) have been extensively detailed in recent years, the effects of CRT on voice and speech quality remain poorly characterized. We investigated changes in patient-reported voice and speech quality (VSQ) after CRT in two prospective studies of organ-sparing CRT for locally advanced oropharyngeal cancer (OPC).
(S030) Utilization of Postprostatectomy Radiation Therapy at an NCI-Designated Comprehensive Cancer CenterApril 15th 2014
To characterize the utilization of postprostatectomy radiation for patients with prostate cancer (CaP) at a National Cancer Institute (NCI)-designated Comprehensive Cancer Center over the past decade, given the introduction of robotic prostatectomy and the publication of multiple phase III trials showing a benefit for adjuvant postprostatectomy radiation.